ERG and central nervous system cancer: Overall, degron loss contributes to many of the most highly recurrent gene fusions specific to particular cancer types (Fig. 3c), including PML-RARA in acute myeloid leukemia (LAML), EGFR-SEPT14 in gliomas, and TMPRSS2-ERG in prostate cancers.